Study Investigating the Pharmacokinetics, Pharmacodynamics and Safety of FE200486
Status:
Completed
Trial end date:
2004-01-01
Target enrollment:
Participant gender:
Summary
Population pharmacokinetic and pharmacodynamic data from Study FE200486 CS06 and FE200486
CS02 provided further knowledge of the optimal dose regimens for FE200486 (degarelix). Both
studies were to guide dose selection for phase III. In addition, safety and tolerance data
were generated.